Alogliptin

BRAND NAMES

The primary brand name for Alogliptin, an oral antidiabetic drug, is Nesina (NESINA), used for the treatment of type 2 diabetes mellitus. Other brand names and combinations include Vipidia (widely used in Europe and other regions), as well as fixed-dose combinations such as Kazano (alogliptin + metformin) and Oseni (alogliptin + pioglitazone), but Nesina and Vipidia are the most commonly recognized standalone brands.

MECHANISM OF ACTION

Alogliptin works by selectively inhibiting the dipeptidyl peptidase-4 (DPP-4) enzyme, which is responsible for the breakdown of incretin hormones such as GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). By blocking DPP-4, alogliptin increases the levels and prolongs the activity of these incretin hormones, leading to enhanced glucose-dependent insulin secretion from pancreatic beta cells and decreased glucagon release from alpha cells. This results in improved blood glucose control, reduced hepatic glucose production, and overall better glycemic regulation in patients with type 2 diabetes mellitus.

PHARMACOKINETICS

Absorption

Alogliptin is orally administered and is rapidly absorbed, reaching peak plasma concentrations approximately 1–2 hours after dosing. The drug has good oral bioavailability, and consistent daily dosing helps maintain effective plasma concentrations for optimal glycemic control.

Distribution

Alogliptin has a moderate volume of distribution, indicating distribution primarily within extracellular fluids and tissues. It exhibits low to moderate plasma protein binding (approximately 20–30%) and does not extensively penetrate the central nervous system. This distribution profile supports its action in peripheral tissues involved in glucose regulation, such as the pancreas and liver.

Metabolism

Alogliptin undergoes minimal metabolism and is primarily excreted unchanged. A small portion is metabolized in the liver, mainly by the CYP2D6 enzyme, but this pathway plays a limited role in its overall clearance. The drug is eliminated through both renal and fecal routes, with a significant proportion excreted unchanged in the urine. Alogliptin has a low potential for clinically significant drug–drug interactions, as it does not strongly inhibit or induce major cytochrome P450 enzymes. However, renal impairment can affect drug elimination and may require dose adjustment and monitoring.

Excretion

Alogliptin is primarily excreted through the urine, with approximately 60–70% eliminated as unchanged drug, and a smaller portion excreted via the feces.

PHARMACODYNAMICS

Alogliptin is a selective, orally active dipeptidyl peptidase-4 (DPP-4) inhibitor that exerts its pharmacodynamic effect by inhibiting the DPP-4 enzyme, thereby increasing the levels of incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which enhance glucose-dependent insulin secretion and reduce glucagon secretion.

ADMINISTRATION

Alogliptin is administered orally, typically at a dose of 25 mg once daily, with or without food. It should be taken at the same time each day to maintain consistent blood levels. Regular medical monitoring is recommended to assess glycemic control and manage potential side effects.

DOSAGE AND STRENGTH

• Recommended dose: 25 mg orally once daily.

• Tablet strengths: Commonly available as 6.25 mg, 12.5 mg, and 25 mg tablets (depending on region).

• Adjustment: Dose modification may be required in patients with renal impairment, as guided by a physician.

• Administration: Can be taken with or without food; consistent daily timing is recommended for optimal effect.

DRUG INTERACTIONS

It is mainly eliminated by the kidneys, drugs affecting renal function may alter its levels. It has minimal effects on other medications and can be taken with or without food, with consistent daily dosing recommended for optimal blood sugar control.

FOOD INTERACTIONS

Alogliptin can be taken with or without food, as its absorption is not significantly affected by meal type. Patients can take it with a regular meal or on an empty stomach without impacting its effectiveness, making it flexible for daily use.

CONTRAINDICATIONS

Alogliptin is contraindicated in patients with a known hypersensitivity to alogliptin or any of its excipients. It should be avoided in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. Caution is advised in patients with severe renal impairment, heart failure, or a history of pancreatitis, as these conditions may increase the risk of adverse effects. Use during pregnancy or breastfeeding should be considered only if clearly needed and under medical supervision.

SIDE EFFECTS

Common side effects of alogliptin include headache, nasopharyngitis (cold-like symptoms), upper respiratory tract infections, and gastrointestinal discomfort such as nausea or stomach pain. Less common effects may include dizziness, hypersensitivity reactions, or joint pain. Rarely, alogliptin can cause pancreatitis or severe allergic reactions. It is generally well tolerated and does not usually cause weight gain or fluid retention.

TOXICITY

Alogliptin toxicity is generally uncommon and usually mild, but can include gastrointestinal symptoms such as nausea or stomach discomfort, as well as headache or dizziness. Rare but serious complications may involve pancreatitis, severe hypersensitivity reactions, or joint pain. Management typically involves discontinuation of the drug and supportive care, with close monitoring of blood glucose levels and pancreatic function when necessary.